Evotec SE, DE0005664809

Evotec wins USD 2.9 million grant as stock slips 0.54% to EUR 2.92

Published on 11/17/2026 at 08:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec has secured a new Gates Foundation grant to extend human stem cell-based drug safety research for three years. On Xetra, the stock closed at EUR 2.94 on Monday, November 16, 2026.

Grant Extends Safety Research

  • Evotec secured a USD 2.9 million Gates Foundation grant for another three years.
  • The project supports earlier screening of potential fetal development risks in drug candidates.
  • More than 5,000 compounds were screened across nine programs during the initial collaboration.
Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec has secured a new USD 2.9 million grant from the Gates Foundation to continue using human stem cell-based methods in early drug safety testing. The three-year award extends a project launched in 2023 and supports global health researchers assessing potential fetal development risks in novel drug candidates.

Evotec's platform combines human induced pluripotent stem cell models with industrial-scale screening. The company said the initial three-year collaboration screened more than 5,000 compounds across nine grantee programs. The approach is designed to give researchers earlier insight into safety risks before drug candidates advance into clinical testing.

According to a PR Newswire release dated Monday, November 16, the funding continues Evotec's work on New Approach Methodologies, which may reduce reliance on animal testing and improve research efficiency.

Evotec stock traded at EUR 2.92 on Lang & Schwarz at 08:00 CET on Tuesday, November 17, 2026, 0.54 percent below the Xetra close of Monday, November 16, 2026, at EUR 2.94.

In the broader market, investors can follow current market reports.

Further developments in Evotec's research partnerships and platform programs remain relevant for the company's long-term growth outlook. More news and analyses on Evotec stock.

Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70525201 | bgmi